Review Article

Nucleic acid and protein methylation modification in renal diseases

Juan Jin1,2, Xue-mei Liu1, Wei Shao1, Xiao-ming Meng3
1 School of Basic Medicine, Anhui Medical University, Hefei 230032, China
2 Research Center for Translational Medicine, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China
3 Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, The Key Laboratory of Anti-Inflammatory of Immune Medicines, Ministry of Education, Hefei 230032, China
Correspondence to: Wei Shao:, Xiao-ming Meng:,
DOI: 10.1038/s41401-023-01203-6
Received: 27 June 2023
Accepted: 18 November 2023
Advance online: 15 December 2023


Although great efforts have been made to elucidate the pathological mechanisms of renal diseases and potential prevention and treatment targets that would allow us to retard kidney disease progression, we still lack specific and effective management methods. Epigenetic mechanisms are able to alter gene expression without requiring DNA mutations. Accumulating evidence suggests the critical roles of epigenetic events and processes in a variety of renal diseases, involving functionally relevant alterations in DNA methylation, histone methylation, RNA methylation, and expression of various non-coding RNAs. In this review, we highlight recent advances in the impact of methylation events (especially RNA m6A methylation, DNA methylation, and histone methylation) on renal disease progression, and their impact on treatments of renal diseases. We believe that a better understanding of methylation modification changes in kidneys may contribute to the development of novel strategies for the prevention and management of renal diseases.
Keywords: renal diseases; AKI; CKD; ccRCC; epigenetic modifications; methylation

Article Options

Download Citation

Cited times in Scopus